Bone level changes after equicrestal versus subcrestal dental implant placement in augmented posterior mandible
Radiographic Evaluation of Crestal Bone Changes Following Equi-crestal Versus Subcrestal Implant Placement in Mandibular Posterior Augmented Ridge. A Randomized Controlled Clinical Trial.
This trial will try whether placing implants slightly below the bone crest (subcrestal) versus level with the crest (equicrestal) leads to less crestal bone loss in adults who had prior mandibular ridge augmentation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 28 (estimated) |
| Ages | 21 Years to 60 Years |
| Sex | All |
| Sponsor | Misr International University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06760442 on ClinicalTrials.gov |
What this trial studies
This is a prospective, parallel randomized controlled trial enrolling 36 participants who previously received horizontal bone augmentation in posterior mandible sites and now need delayed implant placement. Participants are randomized to receive either subcrestal or equicrestal implant placement and will be followed for 18 months. Crestal bone changes will be measured on periapical radiographs at implant placement and at 3, 6, 12, and 18 months, while keratinized tissue width and soft tissue thickness will be measured clinically with a periodontal probe. Buccal bone changes will also be evaluated during the follow-up period.
Who should consider this trial
Good fit: Adults aged 21 or older with previously augmented edentulous posterior mandibular sites (vertical height >10 mm and ridge width ≥7 mm), good oral hygiene, favorable occlusion, and willingness to attend an 18-month follow-up.
Not a fit: Patients who smoke, have systemic conditions or habits that impair healing, inadequate bone volume or active local infection, remaining roots at the site, or who are pregnant are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the approach could reduce crestal bone loss around implants in augmented posterior mandibles, improving long-term implant stability and esthetics.
How similar studies have performed: Previous comparisons of subcrestal versus equicrestal placement have shown mixed results, with some reports of modest reductions in crestal bone loss for subcrestal placement but no clear consensus.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients older than 21 years. * Patients having augmented (by 50/50 particulate xenograft and autogenous bone) edentulous posterior site with vertical bone height of \> 10 mm in the mandible with a width of ridge ≥ 7 mm * Adequate Inter-arch space for implant placement * Favorable occlusion (no traumatic occlusion). * Good oral hygiene.•Accepts 18 months follow-up period (cooperative patient) * The patient provides informed consent. Exclusion Criteria: * Patients with inadequate bone volume and/ or quality * Patients with remaining roots or with signs of acute infection related to the area of interest. * Patients having systemic conditions that interfere with normal wound healing * Patients with habits that may jeopardize the implant longevity and affect the results of the study such as parafunctional habits . * Smoker patients. * Pregnant women.
Where this trial is running
Cairo
- Misr International University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Hani El Nahas Professor, Professor
- Email: hani.elnahass@dentistry.cu.edu.eg
- Phone: 01221334637
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.